However, we found that the migraine days were 16–19 days in three large-scale CGRP trials (Silberstein et al., 2017; Detke et al., 2018; Dodick et al., 2019) and 19 days in two large-scale BoNT-A trials (Aurora et al., 2010; Diener et al., 2010)—indicates that the baseline value might be an unimportant factor in the difference of changes in migraine days. This evidence concerns the gene CALCA and migraine disorder.